30 Other financial income/expense
millions of € |
|
|
|
|---|---|---|---|
|
2020 |
2019 |
2018 |
Income from investments (without share of profit (loss) of associates and joint ventures accounted for using the equity method) |
12 |
(11) |
3 |
Gains (losses) from financial instruments |
628 |
321 |
(352) |
Interest component from measurement of provisions and liabilities |
(531) |
(229) |
(178) |
Gains (losses) from the write-off of other financial assets measured at amortized cost |
0 |
0 |
25 |
|
109 |
81 |
(502) |
All income/expense components including interest income and expense from financial instruments classified as at fair value through profit or loss in accordance with IFRS 9 are reported under other financial income/expense.
Other financial income/expense was unchanged at EUR 0.1 billion, due on the one hand to an increase in interest expense from the measurement of provisions and liabilities. This increase was attributable in particular to the subsequent measurement using actuarial principles of the present value of the provision recognized for the Civil Service Health Insurance Fund (Postbeamtenkrankenkasse – PBeaKK). On the other hand, the gains from financial instruments increased, in particular as a result of the subsequent measurement of the stock options to buy shares in T‑Mobile US received from SoftBank in June 2020. Lower measurement effects from embedded derivatives at T‑Mobile US compared with the prior year had an offsetting effect.
EUR 341 million (2019: EUR -14 million, 2018: EUR 57 million) of other financial income/expense related to currency translation effects, including gains/losses from derivatives used as hedges in foreign-currency hedge accounting, and EUR 287 million (2019: EUR 335 million, 2018: EUR ‑409 million) to gains/losses from other derivatives as well as measurements of equity investments.
For further information on financial instruments, please refer to Note 41 “Financial instruments and risk management.”